Kraken Acquires Institutional-Grade Cryptocurrency Portfolio Reconciliation Solution Interchange, Creates First Full-Service Crypto Trading Platform
Kraken, consistently rated the most secure digital asset exchange and leader in euro volume since 2013, today announced the acquisition of Interchange, a best-in-class accounting, reconciliation and reporting service provider for cryptocurrency hedge funds, asset managers and fund administrators.
The transaction creates the world’s first end-to-end crypto trading and reconciliation platform, and brings Interchange co-founders and well-respected crypto veterans Dan Held and Clark Moody to Kraken.
Interchange offers professional-grade accounting and portfolio reconciliation tools designed specifically for the nuances and complexities of digital asset markets. Founded to improve access to crypto markets, Interchange enables institutional investors to better monitor and report their cryptocurrency holdings. In less than a year, the Interchange team has brought a new, next-generation product to the institutional marketplace, and is servicing over 60 institutions, including fund administrators and hedge funds. Clients including MG Stover, the world’s largest fund administrator for digital asset funds, value the reliability and intuitive nature of the software.
Since 2014, Kraken has registered a triple-digit growth rate (%) in institutional clients year-on-year, and continues to create new and innovative products to address their most persistent challenges. Together with Cryptowatch -- Kraken’s popular multi-exchange charting, trading and portfolio-tracking platform -- Interchange will provide investors and traders with an end-to-end solution to manage and optimize their portfolios.
The addition of Interchange will enable Cryptowatch to offer an unmatched set of products including historical and real-time data; advanced charting; multi-exchange trade execution; research and insights; critical accounting and portfolio reconciliation tools, and world-leading index products via Kraken’s CF Benchmarks business (formerly known as Crypto Facilities Indices). Bringing together this valuable and comprehensive offering in a single venue reinforces Kraken’s commitment to creating a best-in-class platform, supporting the adoption of crypto globally among individuals, professional traders and institutions.
“I couldn’t be more excited to welcome Dan, Clark and the Interchange team to Kraken,” said Jesse Powell, Kraken CEO. “What’s great about Interchange is that it makes accounting, trade reconciliation and reporting so much easier for institutions and individuals trading on Kraken, so our clients can stay focused on tapping the tremendous value that cryptocurrency markets offer.”
“With Interchange, we set out to build best-in-class tools for institutional traders,” said Dan Held, Co-Founder of Interchange. “Becoming part of the Kraken family will enable us to improve our core portfolio reconciliation product, while creating new possibilities for our clients who will now have easy access to Kraken’s cutting-edge suite of products.”
“Interchange is a leading crypto asset management solution and we have always relied on it to simplify accounting in the decentralized, fragmented crypto asset landscape,” said Matt Stover, MG Stover & Co. CEO.
The Interchange acquisition follows the acquisition earlier this month of Cryptofinance.ai, a software tool that provides access to prices and market data from more than 50 exchanges, as well as blockchain network data delivered via Google Sheets. In February this year, Kraken announced its acquisition of Crypto Facilities -- now known as Kraken Futures -- which has been its largest to date. The combination makes Kraken the only regulated exchange to offer spot and futures trading on a single platform.
About Kraken
Based in San Francisco, Kraken is the world’s largest global digital asset exchange in euro volume and liquidity. Kraken’s clients also trade US dollars, Canadian dollars, British pounds, Japanese yen and other digital currencies on a platform consistently rated the best and most secure bitcoin exchange by independent news media.
Founded in 2011, Kraken was the first digital asset exchange to have its market data displayed on the Bloomberg Terminal, the first to pass a cryptographically verifiable proof-of-reserves audit and one of the first exchanges to offer leveraged bitcoin margin trading.
Kraken is trusted by over 4 million traders, institutions and authorities across the world. In 2018 the exchange processed nearly $90 billion in volume while its white-glove OTC desk handled over $2 billion in trades. Since 2016, Kraken has acquired major bitcoin exchanges Coinsetter, Cavirtex and CleverCoin; the award-winning wallet-funding service Glidera; and the popular multi-exchange charting, trading and portfolio tracking platform Cryptowatch, expanding its global reach.
Kraken is backed by investors including Hummingbird Ventures, Blockchain Capital and Digital Currency Group, among others. For more information about Kraken, please visit https://www.kraken.com.
About Interchange
Interchange is solving crypto asset management challenges for businesses. With portfolio accounting, reconciliation, and reporting, Interchange delivers a comprehensive solution for businesses in the crypto asset industry. Growing out of a combination of CoinVantage, formerly a subsidiary of accounting firm MG Stover, and Picks & Shovels, a provider of tools for crypto investors, Interchange delivers mission-critical software products for fund administrators, hedge funds and digital exchanges.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190731005251/en/
Contact information
Kraken
Matt Mason, CMO
press@kraken.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom